Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study

Alexandre Loupy, Olivier Aubert, Babak J Orandi, Maarten Naesens, Yassine Bouatou, Marc Raynaud, Gillian Divard, Annette M Jackson, Denis Viglietti, Magali Giral, Nassim Kamar, Olivier Thaunat, Emmanuel Morelon, Michel Delahousse, Dirk Kuypers, Alexandre Hertig, Eric Rondeau, Elodie Bailly, Farsad Eskandary, Georg Böhmig, Gaurav Gupta, Denis Glotz, Christophe Legendre, Robert A Montgomery, Mark D Stegall, Jean-Philippe Empana, Xavier Jouven, Dorry L Segev, Carmen Lefaucheur, Alexandre Loupy, Olivier Aubert, Babak J Orandi, Maarten Naesens, Yassine Bouatou, Marc Raynaud, Gillian Divard, Annette M Jackson, Denis Viglietti, Magali Giral, Nassim Kamar, Olivier Thaunat, Emmanuel Morelon, Michel Delahousse, Dirk Kuypers, Alexandre Hertig, Eric Rondeau, Elodie Bailly, Farsad Eskandary, Georg Böhmig, Gaurav Gupta, Denis Glotz, Christophe Legendre, Robert A Montgomery, Mark D Stegall, Jean-Philippe Empana, Xavier Jouven, Dorry L Segev, Carmen Lefaucheur

Abstract

Objective: To develop and validate an integrative system to predict long term kidney allograft failure.

Design: International cohort study.

Setting: Three cohorts including kidney transplant recipients from 10 academic medical centres from Europe and the United States.

Participants: Derivation cohort: 4000 consecutive kidney recipients prospectively recruited in four French centres between 2005 and 2014. Validation cohorts: 2129 kidney recipients from three centres in Europe and 1428 from three centres in North America, recruited between 2002 and 2014. Additional validation in three randomised controlled trials (NCT01079143, EudraCT 2007-003213-13, and NCT01873157).

Main outcome measure: Allograft failure (return to dialysis or pre-emptive retransplantation). 32 candidate prognostic factors for kidney allograft survival were assessed.

Results: Among the 7557 kidney transplant recipients included, 1067 (14.1%) allografts failed after a median post-transplant follow-up time of 7.12 (interquartile range 3.51-8.77) years. In the derivation cohort, eight functional, histological, and immunological prognostic factors were independently associated with allograft failure and were then combined into a risk prediction score (iBox). This score showed accurate calibration and discrimination (C index 0.81, 95% confidence interval 0.79 to 0.83). The performance of the iBox was also confirmed in the validation cohorts from Europe (C index 0.81, 0.78 to 0.84) and the US (0.80, 0.76 to 0.84). The iBox system showed accuracy when assessed at different times of evaluation post-transplant, was validated in different clinical scenarios including type of immunosuppressive regimen used and response to rejection therapy, and outperformed previous risk prediction scores as well as a risk score based solely on functional parameters including estimated glomerular filtration rate and proteinuria. Finally, the accuracy of the iBox risk score in predicting long term allograft loss was confirmed in the three randomised controlled trials.

Conclusion: An integrative, accurate, and readily implementable risk prediction score for kidney allograft failure has been developed, which shows generalisability across centres worldwide and common clinical scenarios. The iBox risk prediction score may help to guide monitoring of patients and further improve the design and development of a valid and early surrogate endpoint for clinical trials.

Trial registration: Clinicaltrials.gov NCT03474003.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: support as detailed above for the submitted work; AL holds shares in Cibiltech, a company that develops software; no other relationships or activities that could appear to have influenced the submitted work.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Fig 1
Fig 1
Calibration plots at three, five, and seven years of iBox risk scores for validation cohorts: three year (A, B), five year (C, D), and seven year (E, F) predictions. Data are from European validation cohort (A, C, E) and US cohort (B, D, F). Vertical axis is observed proportion of grafts surviving at time of interest. Average predicted probability (predicted survival; x-axis) was plotted against Kaplan-Meier estimate (observed overall survival; y-axis). Black line represents perfectly calibrated model, and blue line represents optimism corrected iBox model

References

    1. Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015;88:950-7. 10.1038/ki.2015.230
    1. Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0158765. 10.1371/journal.pone.0158765
    1. Evans RW, Manninen DL, Garrison LP, Jr, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-9. 10.1056/NEJM198502283120905
    1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378-83. 10.1111/j.1600-6143.2004.00332.x
    1. Coemans M, Süsal C, Döhler B, et al. Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney Int 2018;94:964-73. 10.1016/j.kint.2018.05.018
    1. Perl J. Kidney transplant failure: failing kidneys, failing care? Clin J Am Soc Nephrol 2014;9:1153-5. 10.2215/CJN.04670514
    1. Stegall MD, Morris RE, Alloway RR, Mannon RB. Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward. Am J Transplant 2016;16:1094-101. 10.1111/ajt.13582
    1. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med 2016;374:333-43. 10.1056/NEJMoa1506027
    1. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 2003;3:1560-5. 10.1046/j.1600-6135.2003.00275.x
    1. He X, Moore J, Shabir S, et al. Comparison of the predictive performance of eGFR formulae for mortality and graft failure in renal transplant recipients. Transplantation 2009;87:384-92. 10.1097/TP.0b013e31819004a1
    1. Naesens M, Lerut E, Emonds MP, et al. Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study. J Am Soc Nephrol 2016;27:281-92. 10.1681/ASN.2015010062
    1. Yilmaz S, Tomlanovich S, Mathew T, et al. Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003;14:773-9. 10.1097/01.ASN.0000054496.68498.13
    1. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010;21:1398-406. 10.1681/ASN.2009101065
    1. Moore J, He X, Shabir S, et al. Development and evaluation of a composite risk score to predict kidney transplant failure. Am J Kidney Dis 2011;57:744-51. 10.1053/j.ajkd.2010.12.017
    1. Shabir S, Halimi JM, Cherukuri A, et al. Predicting 5-year risk of kidney transplant failure: a prediction instrument using data available at 1 year posttransplantation. Am J Kidney Dis 2014;63:643-51. 10.1053/j.ajkd.2013.10.059
    1. Gonzales MM, Bentall A, Kremers WK, Stegall MD, Borrows R. Predicting Individual Renal Allograft Outcomes Using Risk Models with 1-Year Surveillance Biopsy and Alloantibody Data. J Am Soc Nephrol 2016;27:3165-74. 10.1681/ASN.2015070811
    1. Schold JD, Kaplan B. The elephant in the room: failings of current clinical endpoints in kidney transplantation. Am J Transplant 2010;10:1163-6. 10.1111/j.1600-6143.2010.03104.x
    1. Eskandary F, Regele H, Baumann L, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol 2018;29:591-605. 10.1681/ASN.2017070818
    1. Sautenet B, Blancho G, Büchler M, et al. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation 2016;100:391-9. 10.1097/TP.0000000000000958
    1. Rostaing L, Hertig A, Albano L, et al. CERTITEM Study Group Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA. Am J Transplant 2015;15:1303-12. 10.1111/ajt.13132
    1. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015;162:55-63. 10.7326/M14-0697
    1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-62. 10.1111/j.1600-6143.2010.03283.x
    1. Efron B. Bootstrap Methods: Another Look at the Jackknife. Ann Stat 1979;7:1-26 10.1214/aos/1176344552.
    1. Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>;2-4
    1. Pencina MJ, D’Agostino RB, Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21. 10.1002/sim.4085
    1. Uno H, Tian L, Cai T, Kohane IS, Wei LJ. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med 2013;32:2430-42. 10.1002/sim.5647
    1. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation 2009;88:231-6. 10.1097/TP.0b013e3181ac620b
    1. Hosmer DWLS. Applied Logistic Regression. 2nd ed John Wiley & Sons, 2000. 10.1002/0471722146.
    1. Prasad V, Kim C, Burotto M, Vandross A. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Intern Med 2015;175:1389-98. 10.1001/jamainternmed.2015.2829
    1. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12:388-99. 10.1111/j.1600-6143.2011.03840.x
    1. Prémaud A, Filloux M, Gatault P, et al. An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies. PLoS One 2017;12:e0180236. 10.1371/journal.pone.0180236
    1. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40. 10.1002/sim.4780080407

Source: PubMed

3
Suscribir